NCT07122687View on ClinicalTrials.gov

IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

170

Participants

Timeline

Start Date

August 26, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

April 30, 2030

Conditions

Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

Interventions

DRUG

Pemetrexed

500 mg/m2 D1 IV Q3W

DRUG

Cisplatin

75 mg/m2 D1 IV Q3W

DRUG

IBI363

1.5 mg/kg D1 IV Q3W

DRUG

Carboplatin

AUC 5 mg/ml/min D1 IV Q3W

DRUG

Keytruda

200mg D1 IV Q3W

Trial Locations (1)

110000

RECRUITING

Liaoning Cancer Hospital and Institute, Shenyang

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT07122687 - IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter